Scientific Publications & Presentations

• DelMar’s permanent abstract (#TPS2109) at American Society of Clinical Oncology (ASCO)
  (May 31, 2014)
• DelMar’s Interim Data Presentation at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO)
  (May 31, 2014)
• DelMar’s Abstract “In vivo efficacy of VAL-083 in the treatment of non-small cell lung cancer” at American Association of Cancer Research (AACR) Annual Meeting
  (April 9, 2014)
• DelMar’s Presentation Poster “Phase I/II study of VAL-083 in patients with recurrent glioblastoma multiforme” at American Association of Cancer Research (AACR) Annual Meeting
  (April 9, 2014)
• DelMar’s Abstract “Phase I/II study of VAL-083 in patients with recurrent glioblastoma multiforme” at American Association of Cancer Research (AACR) Annual Meeting
  (April 6, 2014)
• DelMar’s Presentation Poster for VAL-083 in Glioblastoma at Society for Neuro-Oncology (SNO) (pdf)
  (December 4, 2013)
• DelMar’s Presentation Poster “The unique mechanism of action of VAL-083 may provide a new treatment option for some chemo-resistant cancers” at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
  (October 21, 2013)
• DelMar’s Presentation Poster from Ongoing Brain Cancer Study at ASCO
  (June 1, 2013)
• DelMar’s Presentation Poster “In vivo efficacy of VAL-083 in the treatment of non-small cell lung cancer” at American Association of Cancer Research (AACR) Annual Meeting
  (April 2013)
• DelMar’s abstract “VAL-083, a novel N7 alkylating agent, surpasses temozolomide activity and inhibits cancer stem cells providing a new potential treatment option for glioblastoma multiforme” at Society for Neuro-Oncology (SNO) Annual Meeting 2012
  (November 2012)
• DelMar’s Presentation Poster “Phase I/II Study of VAL-083 in Patients with Recurrent Malignant Glioma or Progressive-Secondary Brain Tumor” at Society for Neuro-Oncology (SNO) Annual Meeting 2012
  (November 2012)
• DelMar’s abstract “VAL083, a novel N7 alkylating agent, surpasses temozolomide activity and inhibits cancer stem cells providing a new potential treatment option for glioblastoma multiforme” at American Association of Cancer Research (AACR) Annual Meeting
  (April 2012)